Below-forecast US inflation data prompts bets that the Federal Reserve will slow the pace of hikes, boosting emerging market currencies
Choice is between democratic openness and parasitical elites having their way
Regulator says it will soon appoint an interim head
The party has decided there should not be a cooling-off period as provided for in the Electoral Amendment Bill
Department of agriculture says a deal has been struck to release cargoes in Europe, but growers body says industry still faces uncertainty and huge losses
Mike Brown believes it is possible to avoid being greylisted, but much of the work is out of the Treasury’s hands
Employers have offered a multiterm wage agreement for increases of up to 6.2%, but Numsa wants a one-year 20% increase
Former US president says he had ‘no choice’ but to invoke the fifth amendment at attorney-general’s hearing into his business dealings
Fiery hooker comes in as coach Jacques Nienaber reshuffles front row for All Blacks showdown
Now more than ever, there are tangible reasons to believe that Africa’s time is now as major firms invest in African brands, from music and art to fashion
Reading Jasson Urbach’s latest attack on the draft intellectual property (IP) policy (New patents policy the wrong cure for improving access to medicines, September 13) reminds us of the story of the scorpion and the frog, and that doomed river crossing.
Despite the assurance that it was not in his interest to sting the frog, the scorpion just couldn’t help himself. "It’s in my nature," he shrugged as they both drowned.
As a self-styled independent economist, Urbach should know better than to rely largely on the conclusions of a single, contested study. To his credit, he also throws in a red herring and a misplaced quotation from one of SA’s foremost scientists. As a director of the Free Market Foundation and head of its health policy unit, he probably couldn’t help himself.
So let’s start with the single study. For those of us old enough to remember the battles around access to antiretroviral (ARV) medicines in the early 2000s, we’re pretty familiar with the work of Prof Amir Attar...
A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.
Already subscribed? Simply sign in below.
Questions or problems? Email firstname.lastname@example.org or call 0860 52 52 00. Got a subscription voucher? Redeem it now
Would you like to comment on this article? Register (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.